Tucatinib,Trastuzumab,fulvestrant
Seagen
['trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'gicsm', '#gi', 'tucatinib']
tucatinib plus trastuzumab produced responses in 46.7% of patients with previously treated, her2+ metastatic biliary tract cancer. #asco23 #gicsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.